N-(2-二乙基氨基乙基)苯甲酰胺 | 3690-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-二乙基氨基乙基)苯甲酰胺
• 英文名称: N-(2-(diethylamino)ethyl)benzamide
• 英文别名: N-(2-Diethylaminoethyl)benzamid；Bencainamide；N-[2-(diethylamino)ethyl]benzamide
• CAS: 3690-53-7
• 化学式: C₁₃H₂₀N₂O
• mdl: MFCD01183833
• 分子量: 220.315
• InChiKey: ZDQCKWWIYRSDKD-UHFFFAOYSA-N

物化性质

• 沸点：
  361.26°C (rough estimate)
• 密度：
  1.0117 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  苯甲醛 在 叔丁基过氧化氢 、 N-氯代丁二酰亚胺 、 tris(2,2'-bipyridyl)ruthenium dichloride 作用下， 以 乙腈 为溶剂， 反应 27.0h， 生成 N-(2-二乙基氨基乙基)苯甲酰胺
  参考文献：
  名称：

  通过原位酰氯形成的可见光介导的醛和胺合成酰胺

  摘要：

  建立了一种高效的基于可见光光催化的一锅酰胺合成方法。用Ru（bpy）3 Cl 2光催化剂对醛，过氧化叔丁基过氧化氢和N-氯代琥珀酰亚胺的混合物进行可见光照射，得到酰氯，其随后与胺反应以产生相应的酰胺。该反应用于合成吗氯贝胺和D3受体中间体。

  DOI：

  10.1021/acs.joc.5b02726

文献信息

• [EN] NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS<br/>[FR] NOUVEAUX COMPOSES DE BENZAMIDE DESTINES A ETRE UTILISES DANS DES TROUBLES ASSOCIES AU RECEPTEUR DE MCH
  申请人：7TM PHARMA AS

  公开号：WO2004048319A1

  公开（公告）日：2004-06-10

  Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; -SO2NH2, -SO2NHAlk, -SO2NAlk2, -SO2AIk; R8 is hydrogen, halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkoxy groups, dialkylamino groups, -CONHAIk, -CONAIk2, - NHCO-Alk, -CO-Alk, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; X is H, F, Cl, Br, I, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, - CF2CF3, -CF3, -OCF3, -SCF3; OCH3 or lower alkyl or alkenyl group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.

  公开了调节MCH活性的Formula I的新化合物，其中A是连接剂，Ar是芳基或杂环芳基；R1是氢或较低的烷氧基；Q与羰基一起形成酰胺基团，该基团进一步被氨基取代；R5是氢、卤素原子、烷氧基、羟基、烷基氨基基团、二烷基氨基基团、羟基烷基基团、羧酰胺基团、酰胺基团、酰基、-CHO、腈基、烷基、烯基或炔基、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团，如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3；-SO2NH2、-SO2NHAlk、-SO2NAlk2、-SO2AIk；R8是氢、卤素原子、烷基、烯基或炔基、环烷基、烷基环烷基、烷氧基、二烷基氨基基团、-CONHAIk、-CONAIk2、-NHCO-Alk、-CO-Alk、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团，如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3；X是H、F、Cl、Br、I、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团，如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3；OCH3或较低的烷基或烯基基团；这些化合物在治疗或预防肥胖、抑郁症、糖尿病、暴食症等方面是有用的。
• Chloroform as a Carbon Monoxide Precursor: <i>In</i> or <i>Ex Situ</i> Generation of CO for Pd-Catalyzed Aminocarbonylations
  作者：Samuel N. Gockel、Kami L. Hull

  DOI：10.1021/acs.orglett.5b01385

  日期：2015.7.2

  Conditions for the rapid hydrolysis of chloroform to carbon monoxide (CO) using heterogeneous CsOH·H2O are described. CO and 13CO can be generated cleanly and rapidly under mild conditions and can be captured either in or ex situ in palladium-catalyzed aminocarbonylation reactions. Utilizing only 1–3 equiv of CO allows for the aminocarbonylation of aryl, vinyl, and benzyl halides with a wide variety

  描述了使用非均相CsOH·H 2 O将氯仿快速水解为一氧化碳（CO）的条件。CO和13 CO可以在温和的条件下被干净且迅速地产生，并且可以是捕获在或易地在钯催化氨基羰基化反应。仅使用1-3当量的CO可使芳基，乙烯基和苄基卤化物与各种各样的伯胺和仲胺进行氨基羰基化，从而以优异的产率获得酰胺产品。
• Polyamine-substituted ligands for use as contrast agents
  申请人：Wolf Markus

  公开号：US20070202047A1

  公开（公告）日：2007-08-30

  The present invention relates to a polyamine-substituted ligand for the preparation of a contrast agent derived from a chelating molecule selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylentriamine-pentaacetic acid (DTPA), wherein at least one of the carboxylic groups of the chelating molecule is reacted with an amine of formula HNR 1 R 2 to form an amide bond, wherein R 1 , R 2 are independently selected from the group consisting of H; (CH 2 ) n —NR 3 R 4 ; and R 5 ; R 3 , R 4 are independently selected from the group consisting of H; (CH 2 ) m —NR 6 R 7 ; and (CH 2 ) m-1 —CH 3 ; R 6 , R 7 are independently selected from the group consisting of H; and (CH 2 ) o-1 —CH 3 ; n, m, o are independently 2, 3, or 4; R 5 is of formula and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R 1 , R 2 is other than H. Furthermore, the invention relates to contrast agents for magnetic resonance imaging (MRI) comprising said ligands and in-vivo diagnostic methods based on MRI using said contrast agents.

  本发明涉及一种用于制备对比剂的聚胺取代配体，所述对比剂源自从1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸（DOTA）和二乙烯三胺五乙酸（DTPA）组成的羧基配体中选择的螯合分子，其中所述螯合分子的羧基之一与公式HNR1R2的胺反应形成酰胺键，其中R1、R2独立地选择自H；（CH2）n—NR3R4；和R5；R3、R4独立地选择自H；（CH2）m—NR6R7；和（CH2）m-1—CH3；R6、R7独立地选择自H；和（CH2）o-1—CH3；n、m、o独立地为2、3或4；R5为公式，并且可选地，所述螯合分子的羧基之一进一步与具有1至18个碳原子的单烷基胺反应形成酰胺键；前提是R1、R2中至少一个不是H。此外，本发明涉及包括所述配体的磁共振成像（MRI）对比剂以及基于MRI使用所述对比剂的体内诊断方法。
• Small technetium-99m and rhenium labeled agents and methods for imaging tumors
  申请人：President and Fellows of Harvard College

  公开号：US20040097735A1

  公开（公告）日：2004-05-20

  The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

  本发明涉及化合物及其相关的锝和铼配合物，适用于肿瘤的成像或治疗，例如癌瘤、黑色素瘤和其他肿瘤。在另一实施方式中，本发明涉及使用放射标记金属配合物成像肿瘤的方法。用于肿瘤成像的首选放射标记配合物包括锝和铼配合物。本发明的锝配合物具有高肿瘤摄取率和显著的肿瘤/非肿瘤比，表明这种基于锝-99m的小分子探针可以作为黑色素瘤及其转移的体内诊断试剂。在另一实施方式中，本发明涉及使用放射标记金属配合物作为放射药剂来治疗肿瘤的方法。
• Basicity, Lipophilicity, and Lack of Receptor Interaction ofN-Aminoalkylbenzamides andN-Aminoalkyl-o-anisamides as Model Compounds of Dopamine Antagonists
  作者：Lucien Anker、Bernard Testa、Han Van De Waterbeemd、Anne Bornand-Crausaz、Andreas Theodorou、Peter Jenner、C. David Marsden

  DOI：10.1002/hlca.19830660215

  日期：1983.3.16

  N-aminoalkyl-o-methoxybenzamides have been prepared and examined for their pKa, log P and dopamine receptor affinity. The pKa values range from ca. 7.5 for the derivatives having a one-C-atom side-chain, to ca. 10.3 for the N-aminobutyl derivatives. These variations with chain length are satisfactoryly explained by a field model. The variations in (log P)-values as a function of chain length and substitution

  Ñ -Aminoalkylbenzamides和Ñ -aminoalkyl- ö -methoxybenzamides已经制备并检测它们的p ķ一个，登录P和多巴胺受体的亲和性。p K a值的范围从ca。对于具有一个-C原子侧链的衍生物，为约7.5 。10.3为N-氨基丁基衍生物。链长的这些变化可以通过现场模型得到令人满意的解释。（log P）值的变化作为链长和N原子取代的函数，表明存在邻近和构象效应。化合物完全不能取代来自其特定的大鼠纹状体结合位点的3 H-哌啶酮和3 H-磺胺必隆证明了在位置4和5进行足够的芳族取代的关键作用。